Cancer-associated fibroblasts in neoadjuvant setting for solid cancers

Gu, Yanan; Chen, Qiangda; Yin, Hanlin; Zeng, Mengsu; Gao, Shanshan; Wang, Xiaolin

doi:10.1016/j.critrevonc.2023.104226

Cited by 3 publications

(4 citation statements)

References 253 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another important clinical feature of both HY-oAd and 9-ING-41 for cancer therapy is that they are capable of degrading aberrant tumor ECM ( Figure 5A ), which is a well-known barrier against intratumoral penetration and dispersion of various cancer therapeutics and immune cells ( 52 – 54 ). In line with this literature, effective degradation of tumor ECM by HY-oAd and 9-ING-41 was shown to facilitate CD4 + and CD8 + T-cell infiltration into the tumor tissues ( Figures 6B, C , 7B ), as well as simultaneously improving HY-oAd dispersion and accumulation throughout the bladder tumor tissues in a viral replication-independent manner ( Figures 5B , Supplementary Figure S2 ).…”

Section: Discussionmentioning

confidence: 99%

Tumor microenvironment-modulating oncolytic adenovirus combined with GSK-3β inhibitor enhances antitumor immune response against bladder cancer

Yoon,

Jiao,

Hong

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Bladder cancer is a common type of cancer around the world, and the majority of patients are diagnosed with non-muscle-invasive bladder cancer (NMIBC). Although low-risk NMIBC has a good prognosis, the disease recurrence rate and development of treatment-refractory disease remain high in intermediate- to high-risk NMIBC patients. To address these challenges for the treatment of NMIBC, a novel combination therapy composed of an oncolytic adenovirus (oAd) co-expressing interleukin (IL)-12, granulocyte-macrophage colony-stimulating factor (GM-CSF), and relaxin (RLX; HY-oAd) and a clinical-stage glycogen synthase kinase (GSK)-3β inhibitor (9-ING-41; elraglusib) was investigated in the present report. Our findings demonstrate that HY-oAd and 9-ING-41 combination therapy (HY-oAd+9-ING-41) exerted superior inhibition of tumor growth compared with respective monotherapy in a syngeneic NMIBC tumor model. HY-oAd+9-ING-41 induced high-level tumor extracellular matrix (ECM) degradation and a more potent antitumor immune response than the respective monotherapy. In detail, HY-oAd+9-ING-41 induced superior accumulation of intratumoral T cells, prevention of immune cell exhaustion, and induction of tumor-specific adaptive immune response compared to either monotherapy. Collectively, these results demonstrate that the combination of HY-oAd and 9-ING-41 may be a promising approach to elicit a potent antitumor immune response against bladder cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Tumor microenvironment-modulating oncolytic adenovirus combined with GSK-3β inhibitor enhances antitumor immune response against bladder cancer

Yoon,

Jiao,

Hong

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…A significant consequence of CAFs interaction with cancer cells, either through direct contact or indirect paracrine communication, is induced therapy resistance. Particularly, ECM produced by CAFs prevents immune cell infiltration into the TME, hampers drug penetration, and diminishes therapeutic efficacy ( Gu et al, 2024 ). Therefore, therapeutic strategies targeting the communication between cancer cells and their TME are actively explored.…”

Section: Therapeutic Implications and Challengesmentioning

confidence: 99%

“…Therefore, therapeutic strategies targeting the communication between cancer cells and their TME are actively explored. Previous reviews have described in detail the interplay between CAFs and TME and CAFs and immune cells and their role in chemotherapy resistance ( Raskov et al, 2021 ; Gu et al, 2024 ; Piwocka et al, 2024 ). Novel therapeutic approaches include: 1) modulators of gap junctions, 2) integrins blocking antibodies, 3) suppressors of tunnel nanotubes, 4) inhibitors of exosome biogenesis, 5) inhibition of TGFβ and other growth factors cascade, 6) inhibitors of chemokine receptors, and 7) modulators of metabolites ( Dominiak et al, 2020 ).…”

Section: Therapeutic Implications and Challengesmentioning

confidence: 99%

Exploring the multifaceted role of direct interaction between cancer cells and fibroblasts in cancer progression

Dhungel,

Dragoi

2024

Front. Mol. Biosci.

View full text Add to dashboard Cite

The interaction between the tumor microenvironment (TME) and the cancer cells is a complex and mutually beneficial system that leads to rapid cancer cells proliferation, metastasis, and resistance to therapy. It is now recognized that cancer cells are not isolated, and tumor progression is governed among others, by many components of the TME. The reciprocal cross-talk between cancer cells and their microenvironment can be indirect through the secretion of extracellular matrix (ECM) proteins and paracrine signaling through exosomes, cytokines, and growth factors, or direct by cell-to-cell contact mediated by cell surface receptors and adhesion molecules. Among TME components, cancer-associated fibroblasts (CAFs) are of unique interest. As one of the most abundant components of the TME, CAFs play key roles in the reorganization of the extracellular matrix, facilitating metastasis and chemotherapy evasion. Both direct and indirect roles have been described for CAFs in modulating tumor progression. In this review, we focus on recent advances in understanding the role of direct contact between cancer cells and cancer-associated fibroblasts (CAFs) in driving tumor development and metastasis. We also summarize recent findings on the role of direct contact between cancer cells and CAFs in chemotherapy resistance.

show abstract

“…Apart from key genetic factors, desmoplasia and the tumor microenvironment (TME) have been recognized as key contributors to PDAC chemoresistance [ 19 , 20 ], and Gregori et al integrated biomechanical and pharmacological approaches to investigate the role of the cell-adhesion molecule Integrin Subunit Alpha 2 (ITGA2), a crucial regulator of the extracellular matrix [ 21 ], in PDAC resistance to gemcitabine [ 22 ]. Notably, high ITGA2 expression was correlated with shorter progression-free and overall survival, indicating its prognostic significance and association with gemcitabine treatment ineffectiveness.…”

mentioning

confidence: 99%

Revolutionizing Cancer Treatment: Unveiling New Frontiers by Targeting the (Un)Usual Suspects

Costa,

Giovannetti,

Lonardo

2023

Cancers

View full text Add to dashboard Cite

show abstract

Cancer-associated fibroblasts in neoadjuvant setting for solid cancers

Cited by 3 publications

References 253 publications

Tumor microenvironment-modulating oncolytic adenovirus combined with GSK-3β inhibitor enhances antitumor immune response against bladder cancer

Tumor microenvironment-modulating oncolytic adenovirus combined with GSK-3β inhibitor enhances antitumor immune response against bladder cancer

Exploring the multifaceted role of direct interaction between cancer cells and fibroblasts in cancer progression

Revolutionizing Cancer Treatment: Unveiling New Frontiers by Targeting the (Un)Usual Suspects

Contact Info

Product

Resources

About